ITC issues a general exclusion order on infringing tirzepatide imports

The U.S. International Trade Commission issued a general exclusion order on April 9, 2025, blocking the importation of products that contain or purport to contain tirzepatide and that infringe Eli Lilly's trademark or carry a false designation of origin. The Commission also issued cease and desist orders against three named companies: Arctic Peptides, Triggered Brand and Strate Labs. The action was announced in a notice published in the Federal Register on April 15, 2025 ^[1].

Tirzepatide is the active ingredient in Lilly's branded medicines Mounjaro and Zepbound. The ITC investigation, captioned "Certain Products Containing Tirzepatide and Products Purporting to Contain Tirzepatide," covered both actual tirzepatide and products that claim to contain it ^[1].

What a general exclusion order does

Most ITC remedies are limited exclusion orders, which apply only to the companies named as respondents in a case. A general exclusion order is broader: it directs U.S. Customs and Border Protection to stop covered infringing goods at the border regardless of who is shipping them. That means a seller who was never named in the investigation can still have shipments blocked. Cease and desist orders, by contrast, are directed at specific parties — here, Arctic Peptides, Triggered Brand and Strate Labs — and bar them from activities such as selling or distributing covered inventory already inside the United States.

The specific findings behind the order, including the evidence the Commission relied on, the exact scope language of the exclusion order, any bond amount set during the Presidential review period, and the precise date the order takes effect, are not available in the material reviewed for this story. The full Federal Register notice text could not be retrieved ^[1]. Readers looking for those details would need to consult the Commission's published opinion and order documents.

It is also not stated in the available source whether the three named companies participated in the investigation, whether they were found in default, or whether any of them have said they will appeal.

Why it matters for patients

During the tirzepatide shortage, many Americans turned to compounded versions and to online sellers offering vials of powder described as tirzepatide, often labeled "research use only" or "not for human consumption." A general exclusion order aimed at infringing imports targets the supply chain that feeds some of those sellers, because much of the raw peptide material sold this way is imported.

The practical consequence is that some online sources of tirzepatide-labeled products may become harder to find, more expensive, or may disappear without notice. People who have been relying on non-branded sources could face interruptions in what they are able to obtain. It is not known from the available source how quickly enforcement will change what is available for sale, or how many sellers are affected.

There is a second issue embedded in the order's wording. It covers products that "purport to contain" tirzepatide ^[1]. That phrase reflects a known risk with gray-market vials: what is in the container may not match the label. Products sold outside the regulated pharmacy system are not subject to FDA manufacturing oversight, so purity, strength and sterility are not verified by any regulator.

What happens next

The Commission's decision issued April 9, 2025, and the notice published April 15, 2025 ^[1]. Under standard ITC procedure, exclusion orders are subject to a review period before they become final, and parties may seek review in federal court. The available source does not specify the timeline in this case.

Enforcement falls to Customs and Border Protection, which screens incoming shipments. How aggressively small parcel shipments are screened is not addressed in the source material.